Waters acquires Becton Dickinson

Waters Corporation has agreed to acquire Becton Dickinson's Bioscience and Diagnostics division in a deal valued at $17.5 billion. The transaction, structured as a Reverse Morris Trust, received overwhelming approval from Waters' shareholders, with 99% voting in favor. Scheduled to close on February 9, 2026, the acquisition positions Waters to significantly expand its total addressable market to an estimated $40 billion.

The deal will see BD spin off its Bioscience segment, which will merge with a subsidiary of Waters. BD will receive a cash payment of $4 billion, and upon closing, existing Waters shareholders will own approximately 60.8% of the newly formed entity, with BD shareholders holding 39.2%. Waters anticipates achieving $200 million in annual cost synergies by the third year post-closing and aims for a total annual EBITDA of $345 million by 2030. The merger is expected to be accretive to adjusted earnings per share within the first full fiscal year following integration.

Strategically, the acquisition aims to broaden Waters' technological portfolio, allowing the company to integrate BD's clinical diagnostic solutions with its core competencies in mass spectrometry and chromatography. This combination is intended to enhance growth opportunities, particularly in the high-throughput testing markets within the life sciences sector. All required regulatory approvals have been received, including a favorable IRS ruling, facilitating a smooth integration process.

In terms of market dynamics, this acquisition could intensify competition in the biosciences sector as Waters positions itself as a more formidable player with an expanded technological and market footprint. The move could prompt competitors to reassess their strategic positions or pursue similar expansions to maintain market share. Waters' expansion into high-growth areas may also influence capital allocation trends within the industry, as companies seek to capitalize on emerging market opportunities.

As for the financial outlook, Waters is set to report its fourth-quarter and full-year 2025 financial results on February 12, shortly after the deal close. This earnings release will provide a comprehensive view of Waters' performance as a standalone entity before the integration with BD's assets. Management has forecasted revenue growth for Q4 2025 between 5.2% and 7.2%, with adjusted earnings per share expected to range from $4.45 to $4.55. For the full fiscal year, adjusted earnings per share are projected between $13.05 and $13.15.